Welcome to our dedicated page for Covalon Technologies news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on Covalon Technologies stock.
Covalon Technologies Ltd. (CVALF) is described in its news releases as an advanced medical technologies and medical device company with expertise in advanced wound care, vascular access, and surgical consumables. The Covalon news flow often combines clinical, commercial, and financial updates, giving investors and healthcare professionals insight into how its technologies are being adopted and how the business is performing.
Recent announcements include detailed financial results, where the company has reported multiple years of revenue growth, profitability, and a debt-free balance sheet, as well as the declaration and payment of its first-ever special cash dividend. These financial updates are accompanied by commentary on revenue by product category and sales channel, including U.S. Vascular Access and Surgical Consumables, U.S. Advanced Wound Care, and International channels.
Covalon’s news also highlights clinical milestones and conference activity. The company has announced a peer-reviewed study in the Journal of the Association for Vascular Access evaluating its VALGuard ae Vascular Access Line Guard in pediatric central line care, with reported reductions in CLABSI rates. It regularly reports on participation in major professional meetings such as the Association for Vascular Access Annual Scientific Meeting, the Association of Pediatric Hematology/Oncology Nurses Conference, and the ANCC National Magnet & Pathway to Excellence Conference, where it showcases VALGuard ae, CovaClear ae, IV Clear ae, and SurgiClear ae dressings.
Investors following CVALF news can expect updates on quarterly and annual financial results, dividend decisions, board and executive changes, new clinical evidence, health economic findings, and Covalon’s presence at investor conferences such as the Planet MicroCap Showcase. This combination of financial, clinical, and market-facing news provides context on how the company positions its technologies and on the evolution of its business across its key sales channels.
Covalon (OTCQX: CVALF) granted an aggregate of 97,674 Deferred Share Units (DSUs) to four non-employee directors who elected DSU payment for fiscal 2026 fees. The DSUs were issued under the Amended and Restated Omnibus Long-Term Incentive Plan adopted March 25, 2026, and vest 12 months from grant. The deemed value used was the TSX Venture closing price before grant of $1.72 per share.
Covalon (OTCQX: CVALF) reported shareholder approval of all items at its March 25, 2026 Annual General and Special Meeting. 10,157,014 shares (36.777%) were represented. Approved actions include election of directors, PwC appointment, articles amendment to allow preferred shares, amended by-law no.1, advance notice by-law, amended omnibus LTIP, and 150,000 options granted to COO Kim Crooks.
Detailed vote tallies showed strong support for directors and auditors, 89.133% approval for preferred-share authorization, and 96.045% approval for the COO option grant.
Covalon (OTCQX: CVALF, TSXV: COV) will hold its annual meeting of shareholders on Wednesday, March 25, 2026 at 2:00pm ET in a virtual-only format via live webcast.
The meeting will feature a presentation by CEO Brent Ashton and a Q&A session. Registered shareholders and duly appointed proxyholders can attend, participate, and vote online; guests may attend in view-only mode. Meeting access: https://virtual-meetings.tsxtrust.com/en/1871, Meeting ID 1871, Password covalon2026.
Covalon (OTCQX:CVALF) reported fiscal Q1 2026 results for the quarter ended December 31, 2025, with revenue $6.89M, gross margin 58.2%, adjusted EBITDA $426,829, and net income $125,377. Cash was approximately $17.9M after a $4.1M special dividend.
The company highlighted new customer additions, system-wide approval of VALGuard at a 300+ site IDN, a Vizient contract via HARTMANN USA, positive clinical validation reducing CLABSIs, and upcoming industry presentations and a Feb 25, 2026 webcast.
Covalon (OTCQX:CVALF) is sponsoring a continuing-education webinar on IV line contamination and CABSI prevention, presented by vascular access expert Dr. Nancy Moureau and hosted by the Association for Vascular Access (AVA).
The live session is scheduled for Tuesday, February 24, 2026 at 2:00 PM EST with a rebroadcast at 7:00 PM EST, and offers accredited continuing-education credit through AVA.
Covalon (OTCQX: CVALF) will release its Q1 Fiscal 2026 results on Wednesday, February 25, 2026, before markets open. A live conference call and webcast to discuss the results is scheduled for February 25, 2026 at 8:30am ET.
Investors can join via webcast or dial the North American toll-free number; a recording and filings will be available on the company website and SEDAR PLUS.
Covalon Technologies (OTCQX: CVALF) reported fiscal 2025 results for the year ended Sept 30, 2025, with FY revenue of $32.82M, up 5% year-over-year, and Q4 revenue of $8.69M, the company’s highest quarter of FY25.
The company reported FY net income of $2.06M, adjusted EBITDA of $3.71M, gross margin of 53% (56% excluding inventory write-offs), and recorded $715,983 in inventory provisions. Covalon paid its first-ever special dividend of $0.15 CAD per share, leaving cash of $17.0M and no debt as of Dec 5, 2025. Management named Katie Martinovich as CFO. Key commercial wins included a >50% Q4 increase in U.S. vascular access sales and a >$1M initial purchase order from a new U.S. partner for FY26 Q2 delivery.
Covalon Technologies (OTCQX: CVALF) will release its Q4 and year‑end Fiscal 2025 financial results on Thursday, December 11, 2025 before markets open. A conference call and live webcast to discuss results is scheduled for December 11, 2025 at 8:30 AM ET.
Investors can join the webcast at https://events.q4inc.com/attendee/516259946 or dial North American toll‑free 1‑800‑549‑8228 (Local Toronto 289‑819‑1520, Local New York 646‑564‑2877), Conference ID 57487. A recording and copies of the financial statements and MD&A will be available on www.covalon.com under Investors > News & Events and on SEDAR PLUS.
Covalon Technologies (OTCQX: CVALF) announced payment on November 18, 2025 of its first-ever special cash dividend of C$0.15 per common share, payable to shareholders of record as of November 4, 2025. The dividend follows several quarters of profitability and adoption of Covalon’s proprietary medical technologies.
Key financials cited: revenue +82% to $33.0 million, gross margin up from 41% to 56%, and Adjusted EBITDA flipped from -$7.8M to +$4.1M (trailing twelve months vs FY2022). The company cited its VALGuard clinical evidence study and a new CovaClear indication as growth drivers.
Covalon (OTCQX: CVALF, TSXV: COV) declared its first-ever special cash dividend totaling CAD 4,112,711.55 (CAD 0.15 per common share). The dividend is payable on November 18, 2025 to shareholders of record at the close of business on November 4, 2025. The Special Dividend is designated an eligible dividend for purposes of section 89 of the Income Tax Act (Canada).
The company reported a current cash balance of CAD 18.9 million, no debt, and profitability for the last six quarters. The Board stated it may or may not declare additional special dividends in the future. Shareholders do not need to act to receive the payment and are advised to consult financial advisors about tax treatment.